Table 3. Baseline characteristics for subjects with GFR > 60 mL/min/1.73 m2 according to CAVI status.
| CAVI |
p-value | |||
|---|---|---|---|---|
| < 8 | 8–8.9 | ≥ 9 | ||
| (n = 22) | (n = 37) | (n = 85) | ||
| Age (years) | 59.3 ± 9.0 | 62.8 ± 6.3 | 68.4 ± 7.9 | < 0.001 |
| Male (N, %) | 12 (54.6) | 16 (43.2) | 54 (63.5) | 0.111 |
| Body mass index (kg/m2) | 28.1 ± 3.6 | 27.6 ± 3.2 | 25.2 ± 3.1 | < 0.001 |
| Type 2 diabetes (N, %) | 15 (68.2) | 23 (62.2) | 57 (67.1) | 0.847 |
| Hypertension (N, %) | 22 (100) | 37 (100) | 77 (90.6) | 0.053 |
| Chronic kidney disease (N, %) | 2 (9.1) | 7 (18.9) | 10 (11.8) | 0.464 |
| Dyslipidemia (N, %) | 22 (100) | 37 (100) | 82 (96.5) | 0.345 |
| Current smoking (N, %) | 0 | 1 (2.7) | 1 (1.2) | 0.669 |
| Systolic blood pressure (mmHg) | 130.6 ± 10.0 | 134.5 ± 16.1 | 137.9 ± 12.9 | 0.058 |
| Diastolic blood pressure (mmHg) | 73.6 ± 8.4 | 77.3 ± 10.6 | 74.3 ± 8.3 | 0.178 |
| Fasting plasma glucose (mg/dL) | 138.5 ± 49.1 | 122.7 ± 38.3 | 135 ± 44.1 | 0.287 |
| HemoglobinA1C (%) | 7.3 ± 1.7 | 6.7 ± 1.2 | 7.2 ± 1.6 | 0.313 |
| Cholesterol (mg/dL) | 166.9 ± 28.9 | 165.4 ± 34.8 | 164.7 ± 37.8 | 0.972 |
| Triglyceride (mg/dL) | 113.3 ± 74.4 | 116.8 ± 68.5 | 117.5 ± 56.4 | 0.964 |
| HDL cholesterol (mg/dL) | 53.4 ± 11.7 | 55.9 ± 17.3 | 55.9 ± 15.5 | 0.805 |
| LDL cholesterol (mg/dL) | 100.7 ± 27.9 | 95.6 ± 24.9 | 97.9 ± 33.9 | 0.826 |
| Estimated GFR (mL/min/1.73 m2) | 83.4 ± 16.1 | 82.7 ± 12.9 | 79.9 ± 13.7 | 0.439 |
| Median decline of estimated GFR (mL/min/1.73 m2 per year) | −0.6 (−5.2 to 4.6) | −1.2 (−11.3 to −0.6) | −6.8 (−9.7 to −0.9) | 0.004 |
CAVI; Cardio-ankle vascular index, GFR; Glomerular filtration rate